ArticleCells2021
Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways.
Open access · goldAbstract read
In one paragraph
Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
7.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Mapping the knowledge domain: a bibliometric analysis of global research on traditional Chinese medicine for non-alcoholic fatty liver disease (2000-2024).Frontiers in medicine · 2026Pooled it
- Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.International journal of molecular sciences · 2024Pooled it
- Natural products and dietary interventions on liver enzymes: an umbrella review and evidence map.Frontiers in nutrition · 2024Pooled it
- Multi-Compartment Metabolic Remodeling in DRA-Deficient Mice Overlaps with Ulcerative Colitis Metabolic Signatures.Metabolites · 2026Article
- Bile acid dependent attenuation of toxin mediated disease is independent of colonization resistance againstbioRxiv : the preprint server for biology · 2026Article
- Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities.Pharmacological reviews · 2026Review
- Regulation of bile acids homeostasis: a feasible and versatile way to treat or diagnose liver disorders.Frontiers in nutrition · 2026Review
- Immunometabolic pathways in liver fibrosis: current evidence for selected plant-derived metabolites associated with traditional Chinese medicine.Frontiers in pharmacology · 2026Review
- Bile Acid Analogs with Anti-Germination Activities for Prophylaxis ofBiomolecules · 2025Article
- Bile acid dysmetabolism in Bangladeshi infants associated with poor linear growth, enteric inflammation, and small intestine bacterial overgrowth.World journal of gastroenterology · 2025Article
- Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation.Nature communications · 2025Article
- Transcriptomics, lipidomics, and single-nucleus RNA sequencing integration: exploring sphingolipids in MASH-HCC progression.Cell & bioscience · 2025Article
- Liver specific transgenic expression of CYP7B1 attenuates early western diet-induced MASLD progression.Journal of lipid research · 2025Article
- Gut Microbiome and Bile Acid Interactions: Mechanistic Implications for Cholangiocarcinoma Development, Immune Resistance, and Therapy.The American journal of pathology · 2025Review
- Exploring the Mechanism of Modified Zexie Decoction Against Metabolic Associated Fatty Liver Disease Based on Network Pharmacology and Experimental Validation.Combinatorial chemistry & high throughput screening · 2025Article
- A critical review of natural products driven correction of bile acid dysregulation: a therapeutic strategy for nonalcoholic fatty liver disease.Frontiers in pharmacology · 2025Review
- Total alkaloids fromFrontiers in pharmacology · 2025Article
- Therapeutic potential of traditional Chinese medicine in pancreatic fibrosis: mechanisms of TCM formulas and active ingredients.Frontiers in pharmacology · 2025Review
- Berberine pharmacological properties and therapeutic potential across cancer, digestive, metabolic, cardiovascular, and neurological diseases: an update review.EXCLI journal · 2025Review
- Pharmacological properties and therapeutic potential of berberine: a comprehensive review.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 3 countries.
Yanyan WangDepartment of Microbiology and Immunology, Medical College of Virginia and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA 23298, USA.
Yun-Ling TaiDepartment of Microbiology and Immunology, Medical College of Virginia and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA 23298, USA.
Derrick ZhaoDepartment of Microbiology and Immunology, Medical College of Virginia and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA 23298, USA.
Yuan ZhangDepartment of Microbiology and Immunology, Medical College of Virginia and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA 23298, USA.
Junkai YanDepartment of Microbiology and Immunology, Medical College of Virginia and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA 23298, USA.
Genta KakiyamaDepartment of Internal Medicine, Medical College of Virginia and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Xuan WangDepartment of Microbiology and Immunology, Medical College of Virginia and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA 23298, USA.
Emily C GurleyDepartment of Microbiology and Immunology, Medical College of Virginia and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA 23298, USA.
Jinze LiuDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Jinpeng LiuDepartment of Computer Science, University of Kentucky, Lexington, KY 40506, USA.
Jimin LiuDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L6M0L8, Canada.
Guanhua LaiDepartment of Pathology, Medical College of Virginia, 23298 Virginia Commonwealth University, Richmond, VA 23298, USA.
Phillip B HylemonDepartment of Microbiology and Immunology, Medical College of Virginia and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA 23298, USA.
William M PandakDepartment of Internal Medicine, Medical College of Virginia and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Weidong ChenSchool of Pharmaceutical Science, Anhui University of Chinese Medicine, Qianjiang, Hefei 230012, China.
Huiping ZhouDepartment of Microbiology and Immunology, Medical College of Virginia and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA 23298, USA.
Virginia Commonwealth University · USUniversity of Kentucky · USVirginia Commonwealth University Medical Center · USAnhui University of Traditional Chinese Medicine · CN
Funding
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0MRegulation of Hepatic SphK2 by Bile Acids: Effects on Lipid MetabolismR01DK057543 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI HYLEMON, PHILLIP B, ZHOU, HUIPING ROSE · 2001 to 2015
$4.4MBile Acid and Sphingosine-1-phosphate Receptor-mediated Signaling in CholestasisR01DK104893 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI HYLEMON, PHILLIP B, ZHOU, HUIPING ROSE · 2016 to 2020
$2.0MBLRD VA I01 BX000197NCI NIH HHS P30 CA016059NIDDK NIH HHS R01 DK057543NIDDK NIH HHS R01 DK104893U.S. Department of Veterans Affairs I01BX004033; Research Career Scientist Award (IK6BX004477); ShEEP grant (1 IS1 BX004777-01)
Abstract
The disease progression of nonalcoholic fatty liver disease (NAFLD) from simple steatosis (NAFL) to nonalcoholic steatohepatitis (NASH) is driven by multiple factors. Berberine (BBR) is an ancient Chinese medicine and has various beneficial effects on metabolic diseases, including NAFLD/NASH. However, the underlying mechanisms remain incompletely understood due to the limitation of the NASH animal models used.
Indexed as
Disease ProgressionSignal TransductionAnimalsBerberineBile Acids and SaltsDiet, WesternFatty AcidsGene Expression ProfilingGene OntologyLipid MetabolismMiceMice, Inbred C57BLModels, BiologicalNon-alcoholic Fatty Liver DiseaseOxidative StressTranscriptomeBerberineBile Acids and SaltsFatty Acidsbile acidsfibrosisinflammationNAFLD
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.